Bullshit Memorization Stuff Flashcards
Fabry disease - deficient enzyme and accumulated substrate
Enzyme: alpha-galactosidase A
Accumulated substrate: ceramide trihexoside (globotriaosylceramide)
XR
Gaucher disease - deficient enzyme and accumulated substrate
Enzyme: glucocerebrosidase (beta-glucosidase)
Accumulated substrate: glucocerebroside
AR
Niemann-Pick disease - deficient enzyme and accumulated substrate
Enzyme: sphingomyelinase
Accumulated substrate: sphingomyelin
AR
Tay-Sachs disease - deficient enzyme and accumulated substrate
Enzyme: hexosaminidase A
Accumulated substrate: GM2 ganglioside
AR
Krabbe disease - deficient enzyme and accumulated substrate
Enzyme: galactocerebrosidase
Accumulated substrate: galactocerebroside, psychosine
AR
Metachromatic leukodystrophy - deficient enzyme and accumulated substrate
Enzyme: arylsulfatase A
Accumulated substrate: cerebroside sulfate
AR
Hurler syndrome - deficient enzyme and accumulated substrate
Enzyme: alpha-L-iduronidase
Accumulated substrate: heparan sulfate, dermatan sulfate
AR
Hunter syndrome - deficient enzyme and accumulated substrate
Enzyme: iduronate sulfatase
Accumulated substrate: heparan sulfate, dermatan sulfate
XR
sensitivity - define, equation
proportion of all people w/ disease who test positive, or probability that a test detects dz when a dz is present
sensitivity = TP/(TP+FN)
specificity - define, equation
proportion of all people w/o dz who test negative, or probability that test indicates no dz when dz is absent
specificity = TN/(TN+FP)
positive predictive value - define, equation
proportion of positive test results that are true positive
PPV = TP/(TP+FP)
negative predictive value - define, equation
proportion of negative test results that are true negative
NPV = TN/(TN+FN)
odds ratio - define, equation
odds that the group w/ the dz (cases) was exposed to a risk factor divided by odds that group w/o dz was exposed; typically used in case-control studies
OR = (a/c)/(b/d) = ad/bc = (a/b)/(c/d)
relative risk - define, equation
risk of developing dz in the exposed group divided by risk in the unexposed group; typically used in cohort studies
RR = a/(a+b)/c/(c+d)
attributable risk - define, equation
difference in risk b/w exposed and unexposed groups, or proportion of dz occurrences that are attributable to exposure
AR = a/(a+b) - c/(c+d)
relative risk reduction - define, equation
proportion of risk reduction attributable to intervention as compared to a control
RRR = 1 - RR
absolute risk reduction - define, equation
difference in risk (not the proportion) attributable to intervention as compared to control
ARR = c/(c+d) - a/(a+b)
number needed to treat - define, equation
number of pts who need to be treated for 1 pt to benefit
NNT = 1/ARR
number needed to harm - define, equation
number of pts who need to be exposed to a risk factor for 1 pt to be harmed
NNH = 1/AR
Reynold’s pentad for cholangitis
Jaundice, Fever, RUQ pain, hypotension, AMS
stimulates bone and muscle growth
GH -> IGF-1
stimulates milk production
prolactin
stimulates milk secretion during lactation
oxytocin
responsible for female secondary sex characteristics
estrogen (estradiol primarily)
stimulates metabolic activity
T3/T4
increases blood glucose level and decreases protein synthesis
glucocorticoids
responsible for male secondary sex characteristics
testosterone
prepares endometrium for implantation/maintenance of pregnancy
progesterone
stimulates adrenal cortex to synthesize and secrete cortisol
ACTH
stimulates follicle maturation in females and spermatogenesis in males
FSH
increases plasma calcium, increases bone resorption
PTH
decreases plasma calcium, increases bone formation
calcitonin
stimulates ovulation in females and testosterone synthesis in males
LH
stimulates thyroid to produce TH and uptake iodine
TSH
GH secreted from?
anterior pituitary
T3/T4 secreted from?
thyroid
glucocorticoids secreted from?
adrenal cortex (zona fasciculata)
progesterone secreted from?
ovaries
prolactin secreted from?
anterior pituitary
oxytocin secreted from?
hypothalamus (paraventricular nucleus) -> stored in posterior pituitary
ANP/ANH secreted from?
atria of heart
glucagon secreted from?
alpha cells of pancreas
testosterone secreted from?
testes in men, ovaries in women
FSH secreted from?
anterior pituitary
vasopressin/ADH secreted from?
hypothalamus (supraoptic nucleus) -> stored in posterior pituitary
calcitonin secreted from?
parafollicular “c” cells of thyroid
TSH secreted from?
anterior pituitary
epinephrine and norepinephrine secreted from?
chromaffin cells of adrenal medulla
insulin secreted from?
beta cells of pancreas
estradiol secreted from?
ovaries
estriol secreted from?
placenta
estrone secreted from?
fat
estrogen in males secreted from?
testes
PTH secreted from?
parathyroids
somatostatin secreted from?
delta cells of pancreas
LH secreted from?
anterior pituitary
mineralocorticoids secreted from?
adrenal cortex (zona glomerulosa)
ACTH secreted from?
anterior pituitary
HIV drug ADR: GI intolerance
protease inhibitors
HIV drug ADR: inhibit cytochrome P450
protease inhibitors (especially ritonavir)
HIV drug ADR: hyperlipidemia/hypertriglyceridemia
protease inhibitors
HIV drug ADR: lipodystrophy
protease inhibitors
HIV drug ADR: pancreatitis
ritonavir, didanosine
HIV drug ADR: nephrolithiasis
indinavir, atazanavir
HIV drug ADR: increased bilirubin
atazanavir
HIV drug ADR: bone marrow suppression
zidovudine
HIV drug ADR: pancreatitis and peripheral neuropathy
didanosine, zalcitabine, stavudine
HIV drug ADR: hepatic steatosis
didanosine, stavudine
HIV drug ADR: hypersensitivity reaction
abacavir
HIV drug ADR: rash
NNRTIs
HIV drug ADR: neuropsychiatric sx (nightmares, vivid dreams, dizziness, worsening depression)
efavirenz
false-positive drug test to cannabinoids
efavirenz
HIV drug ADR: teratogenic
efavirenz
which glycogen storage disease has lactic acidosis, hyperlipidemia, hyperuricemia (gout)
Von Gierke
which glycogen storage disease has cardiomegaly
Pompe (infantile)
which glycogen storage disease has diaphragm weakness, leading to respiratory failure
Pompe (adult)
which glycogen storage disease has increased glycogen in liver, severe fasting hypoglycemia
von Gierke
which glycogen storage disease has hepatomegaly, hypoglycemia, hyperlipidemia (normal kidneys, lactate, uric acid)
Cori
which glycogen storage disease has painful cramps, myoglobinuria with strenuous exercise
McArdle
which glycogen storage disease has severe HSM, enlarged kidneys
Von gierke
rate-limiting enzyme of glycolysis
phosphofructokinase-1 (PFK-1)
rate-limiting enzyme of gluconeogenesis
fructose-1,6-bisphosphatase
rate-limiting enzyme of TCA cycle
isocitrate dehydrogenase
rate-limiting enzyme of glycogenesis
glycogen synthase
rate-limiting enzyme of glycogenolysis
glycogen phosphorylase
rate-limiting enzyme of HMP shunt
glucose-6-phosphate dehydrogenase (G6PD)
rate-limiting enzyme of de novo pyrimidine synthesis
carbamoyl phosphate synthetase II
rate-limiting enzyme of de novo purine synthesis
glutamine-phosphoribosylpyrophosphate (PRPP) amidotransferase
rate-limiting enzyme of urea cycle
carbamoyl phosphate synthetase I
rate-limiting enzyme of fatty acid synthesis
acetyl-CoA carboxylase (ACC)
rate-limiting enzyme of fatty acid oxidation
carnitine acyltransferase/palmitoyltransferase I (CAT I/CPS I)
rate-limiting enzyme of ketogenesis
HMG-CoA synthase
rate-limiting enzyme of cholesterol synthesis
HMG-CoA reductase
rate-limiting enzyme of bile acid synthesis
7alpha-hydroxylase
HLA: hemochromatosis
HLA-A3
HLA: PAIR dzs
HLA-B27
HLA: Celiac dz
HLA-DQ2/DQ8
HLA: MS, Goodpasture syndrome
HLA-DR2
HLA: DM type I, Graves, Hashimoto
HLA-DR3
HLA: RA, DM type I
HLA-DR4
HLA: pernicious anemia, Hashimoto
HLA-DR5
anti-ACh receptor ab
MG
anti-basement membrane ab
Goodpasture syndrome
anticardiolipin, lupus anticoagulant ab
SLE, antiphospholipid antibody syndrome
anticentromere ab
limited scleroderma (CREST syndrome)
anti-desmosome (anti-desmoglein) ab
pemphigus vulgaris
anti-dsDNA, anti-Smith (snRNP) ab
SLE
anti-glutamic acid decarboxylase (GAD-65) ab
DM type 1
antihemidesmosome ab
bullous pemphigoid
anti-histone ab
drug-induced lupus
anti-Jo-1 (anti-histidyl-tRNA synthetase), anti-SRP, anti-Mi-2 abs
polymyositis, dermatomyositis
antimicrosomal, antithyroglobulin abs
Hashimoto thyroiditis
antimitochondrial ab
primary biliary cirrhosis
antinuclear antibodies (ANCA) ab
SLE, nonspecific
antiparietal cell ab
pernicious anemia
anti-Scl-70 (anti-DNA topoisomerase I) ab
diffuse scleroderma
anti-smooth muscle, anti-ANA abs
autoimmune hepatitis (type I)
anti-SSA, anti-SSB (anti-Ro, anti-La) abs
Sjogren syndrome
anti-TSH receptor ab
Graves dz
anti-U1 RNP (ribonucleoprotein) ab
mixed connective tissue dz
IgA anti-endomysial, IgA anti-tissue transglutaminase abs
Celiac dz
MPO-ANCA/p-ANCA ab
microscopic polyangiitis, eosinophilic granulomatosis w/ polyangiitis (Churg-Strauss syndrome)
PR3-ANCA/c-ANCA ab
granulomatosis w/ polyangiitis (Wegeners)
rheumatoid factor (IgM ab that targets IgG Fc region), anti-CCP (more specific) abs
RA
anti-liver-kidney microsomal, anti-liver cytosol abs
autoimmune hepatitis (type II)
alemtuzumab target
CD52
bevacizumab target
VEGF
cetuximab target
EGFR
rituximab target
CD20
trastuzumab target
HER2/neu
adalimumab, infliximab target
soluble TNF-alpha
etanercept target
decoy TNF-alpha receptor
exulizumab target
complement protein C5
natalizumab target
alpha4-integrin
abciximab target
platelet glycoproteins IIb/IIIa
denosumab target
RANKL
digoxin immune Fab target
digoxin (antidote for dig toxicity)
omalizumab target
IgE
palivizumab target
RSV F protein
ranibizumab, bevacizumab target
VEGF
muromonab target
CD3 on T cells
BCR-ABL: gene product and associated tumor(s)
tyrosine kinase
CML, ALL
BCL-2: gene product and associated tumor(s)
antiapoptotic molecule (inhibits apoptosis) follicular and undifferentiated lymphomas
BRAF: gene product and associated tumor(s)
serine/threonine kinase
melanoma, non-Hodgkin lymphoma
c-kit: gene product and associated tumor(s)
cytokine receptor
gastrointestinal stromal tumor (GIST)
c-myc: gene product and associated tumor(s)
transcription factor
Burkitt lymphoma
HER2/neu (c-erbB2): gene product and associated tumor(s)
tyrosine kinase
breast, ovarian, and gastric carcinomas
L-myc: gene product and associated tumor(s)
transcription factor
lung tumor
N-myc: gene product and associated tumor(s)
transcription factor
neuroblastoma
RAS: gene product and associated tumor(s)
GTPase
K-RAS: Kolon, panKreatic, lung cancer
H-RAS: bladder and kidney (Hematuria)
N-RAS: melanoma, hematologic, follicular thyroid
MC mutation in human tumors (15-20% have it)
RET: gene product and associated tumor(s)
tyrosine kinase
MEN 2A and 2B, medullary thyroid cancer
APC: gene product and associated tumor(s)
(no listed gene product) colorectal cancer (associated w/ FAP)
BRCA1/BRCA2: gene product and associated tumor(s)
DNA repair protein
breast (1 and 2), ovarian (1), and prostate cancer (1)
DCC: gene product and associated tumor(s)
DCC: Deleted in Colon Cancer
colon cancer
DPC4/SMAD4: gene product and associated tumor(s)
DPC: Deleted in Pancreatic Cancer
pancreatic cancer
MEN1: gene product and associated tumor(s)
menin
MEN 1
NF1: gene product and associated tumor(s)
Ras GTPase activating protein (neurofibromin)
NF1 (von Recklinghausen dz)
NF2: gene product and associated tumor(s)
merlin (schwannomin) protein
NF2
p16: gene product and associated tumor(s)
cyclin-dependent kinase inhibitor 2A
melanoma
p53: gene product and associated tumor(s)
transcription factor for p21, blocks G1 -> S phase
most human cancers, Li-Fraumeni syndrome
>50% of human cancers have this mutation!
PTEN: gene product and associated tumor(s)
(no listed gene product)
breast cancer, prostate cancer, endometrial cancer
Rb: gene product and associated tumor(s)
inhibits E2F; blocks G1 -> S phase
retinoblastoma, osteosarcoma, breast, colon, and lung cancers
TSC1: gene product and associated tumor(s)
hamartin protein
tuberous sclerosis
TSC2: gene product and associated tumor(s)
tuberin protein
tuberous sclerosis
VHL: gene product and associated tumor(s)
inhibits hypoxia inducible factor 1a
von Hippel-Lindau dz, RCC
WT1/WT2: gene product and associated tumor(s)
(no listed gene product) Wilms tumor (nephroblastoma)
alkaline phosphatase (tumor marker)
mets to bone or liver, Paget dz of bone, seminoma (placental ALP)
alpha-fetoprotein (tumor marker)
HCC, hepatoblastoma, yolk sac (endodermal sinus) tumor, mixed germ cell tumor
beta-HCG (tumor marker)
hydatidiform moles and choriocarcinomas (gestational trophoblastic dz), testicular cancer, mixed germ cell tumor
CA 15-3/CA 27-29 (tumor marker)
breast cancer
CA 19-9 (tumor marker)
pancreatic cancer
CA 125 (tumor marker)
ovarian cancer (any peritoneal irritation increases CA 125)
calcitonin (tumor marker)
medullary thyroid carcinoma
CEA (tumor marker)
very nonspecific, but ~70% of colon and pancreatic cancers produce; also made by gastric, breast, and medullary thyroid carcinomas
chromogranin (tumor marker)
neuroendocrine tumors/carcinoid
PSA (tumor marker)
prostate cancer; can also be elevated in BPH and prostatitis, questionable risk/benefit
S-100 (tumor marker)
melanoma, Schwannoma
tartrate-resistant acid phosphatase (TRAP) (tumor marker)
hairy cell leukemia
anti-Yo, anti P/Q, and anti-Hu abs
paraneoplastic cerebellar degeneration
renal clearance equation
C = UV/P
GFR equation
GFR = U(inulin)V/P(inulin) = C(inulin)
inulin freely filtered, neither reabsorbed nor secreted
most of the time use creatinine clearance (approximate; slightly overestimates d/t moderate secretion)
effective renal plasma flow equation
renal blood flow equation
eRPF = U(PAH)V/P(PAH) = C(PAH)
PAH both filtered and secreted
RBF = RPF/(1 - Hct)
filtration fraction equation
FF = GFR/RPF; normal 20%
filtered load equation
GFR x Px
Winters formula
predicted respiratory compensation for simple metabolic acidosis; if measured PCO2 differs significantly from predicted, mixed acid-base disorder likely
PCO2 = 1.5[HCO3-] + 8 +/- 2
anion gap calculation
Na+ - (Cl- + HCO3-)
normal range: 10-12